As per the report published by The Brainy Insights, the global liquid biopsy market was valued at USD 10.85 billion in 2023, increasing at a CAGR of 11.61% from 2024 to 2033 and anticipated to reach USD 32.54 billion by 2033. North America emerged as the largest market for the global liquid biopsy market, with a 48.11% share of the market revenue in 2023.  The more significant investments and the presence of biotechnology companies developing the tests propel the market's growth in this region. Furthermore, the high demand for various surgical procedures, the introduction of extensive genome sequencing initiatives, and the increased research funding from the national cancer institute are helping to drive the market growth in this region. In addition, the Asia Pacific region is expected to show the fastest CAGR growth over the projection period due to the ever-increasing incidence of specific diseases and a growing emphasis on the key market players.

Request PDF sample at: https://www.thebrainyinsights.com/enquiry/sample-request/13005

Leading companies in the industry include CareDx Inc., Eurofins Scientific, Exact Sciences Corporation, Immucor, Inc., MDxHealth, Menarini Silicon Biosystems, GUARDANT HEALTH, INC, Thermo Fisher Scientific Inc., Illumina, Inc., Genomic Health, Myriad Genetics, Inc., RainDance Technologies Inc., QIAGEN, Exosome Diagnostics, Biocept, Inc, LungLife AI, Inc., Natera, Inc., Trovagene, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., and among others which are offering greater opportunities and are continuously focused on new product developments and venture capital investments to obtain market share.

The biomarker types segment is divided into circulating tumor DNA (CTDNA), circulating tumor cells (CTCs), extracellular vesicles (EVS), and others. The circulating tumor DNA (CTDNA) segment led the market with a market share of 32.12% in 2022. This growth is attributed to the rising application of polymerase chain reaction (PCR) in research and forensic laboratories. The sample segment is divided into the urine sample, blood sample, and others. The blood sample segment led the market with a market share of 42.14% in 2022. This growth is attributed to the increasing demand for minimally invasive diagnostic tests. The end-user segment is divided into academic and research centers, hospitals and laboratories, and others. The hospitals and laboratories segment led the market with a market share of 41.24% in 2022. This growth is attributed to the increasing burden of chronic diseases and the growing demand for early diagnostic tests. The technology segment is divided into the single-gene analysis (PCR Microarrays) and multi-gene-parallel analysis (NGS). The multi-gene-parallel analysis (NGS) segment led the market with a market share of 56.18% in 2022. This growth is attributed to the increasing genome mapping program.

Read Detailed Index of full Research Study at @ https://www.thebrainyinsights.com/report/liquid-biopsy-market-13005

The increasing prevalence of cancer, along with growing public & private funding to support research activities, are propelling the liquid biopsy market's growth. Further, the rapid development in digital Polymerase Chain Reaction (PCR) and NGS-based technology, a rise in patient preference for minimally invasive treatments, and other technological upgradation and advancements are helping to stimulate the liquid biopsy market growth.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D

Head of Business Development

Phone: +1-315-215-1633

Email: sales@thebrainyinsights.com

Web: www.thebrainyinsights.com